93 related articles for article (PubMed ID: 34751409)
1. KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells.
Frazzi R; Cusenza VY; Pistoni M; Canovi L; Cascione L; Bertoni F; Merli F
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751409
[TBL] [Abstract][Full Text] [Related]
2. A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine.
Jacobberger JW; Woost PG
Methods Cell Biol; 2024; 186():131-150. PubMed ID: 38705597
[TBL] [Abstract][Full Text] [Related]
3. Arsenic disulfide promoted the demethylation of
Chen C; Wang L; Liu Y; Du S; Teng Q
PeerJ; 2024; 12():e17363. PubMed ID: 38766487
[TBL] [Abstract][Full Text] [Related]
4. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.
Datta J; Ghoshal K; Denny WA; Gamage SA; Brooke DG; Phiasivongsa P; Redkar S; Jacob ST
Cancer Res; 2009 May; 69(10):4277-85. PubMed ID: 19417133
[TBL] [Abstract][Full Text] [Related]
5. Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells.
Pang J; Shen N; Yan F; Zhao N; Dou L; Wu LC; Seiler CL; Yu L; Yang K; Bachanova V; Weaver E; Tretyakova NY; Liu S
Oncotarget; 2017 May; 8(21):34453-34467. PubMed ID: 28415607
[TBL] [Abstract][Full Text] [Related]
6. A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target.
Yan F; Shen N; Pang JX; Zhao N; Zhang YW; Bode AM; Al-Kali A; Litzow MR; Li B; Liu SJ
Leukemia; 2018 Apr; 32(4):865-873. PubMed ID: 28993705
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of TFPI-2 in canine diffuse large B-cell lymphoma.
Ferraresso S; Bresolin S; Aricò A; Comazzi S; Gelain ME; Riondato F; Bargelloni L; Marconato L; Kronnie Gt; Aresu L
PLoS One; 2014; 9(4):e92707. PubMed ID: 24695110
[TBL] [Abstract][Full Text] [Related]
8. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract][Full Text] [Related]
9. A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma.
Bethge N; Honne H; Andresen K; Hilden V; Trøen G; Liestøl K; Holte H; Delabie J; Lind GE; Smeland EB
PLoS One; 2014; 9(9):e104249. PubMed ID: 25226156
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab.
Zhao H; Zhang LE; Guo S; Yuan T; Xia B; Zhang L; Zhang Y
Oncol Lett; 2015 May; 9(5):2307-2312. PubMed ID: 26137062
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide methylation profiling of Peripheral T-cell lymphomas identifies TRIP13 as a critical driver of tumor proliferation and survival.
Nowialis P; Tobon J; Lopusna K; Opavska J; Badar A; Chen D; Abdelghany R; Pozas G; Fingeret J; Noel E; Riva A; Fujiwara H; Opavsky R
Res Sq; 2024 Feb; ():. PubMed ID: 38464090
[TBL] [Abstract][Full Text] [Related]
12. GSK-3484862 targets DNMT1 for degradation in cells.
Chen Q; Liu B; Zeng Y; Hwang JW; Dai N; Corrêa IR; Estecio MR; Zhang X; Santos MA; Chen T; Cheng X
NAR Cancer; 2023 Jun; 5(2):zcad022. PubMed ID: 37206360
[TBL] [Abstract][Full Text] [Related]
13. Harnessing lymphoma epigenetics to improve therapies.
Yang H; Green MR
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):95-100. PubMed ID: 33275741
[TBL] [Abstract][Full Text] [Related]
14. The Association of Methylation Status and Expression Level of
Khojastehpour S; Foroughi F; Gheibi N; Mohammadi Z; Ahmadi MH; Nasirian N; Maali A; Azad M
Int J Hematol Oncol Stem Cell Res; 2023 Jul; 17(3):133-144. PubMed ID: 37817971
[No Abstract] [Full Text] [Related]
15. Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation.
Zwergel C; Fioravanti R; Stazi G; Sarno F; Battistelli C; Romanelli A; Nebbioso A; Mendes E; Paulo A; Strippoli R; Tripodi M; Pechalrieu D; Arimondo PB; De Luca T; Del Bufalo D; Trisciuoglio D; Altucci L; Valente S; Mai A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32075099
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DNA methylation in proliferating human lymphoma cells by immune cell oxidants.
O'Connor KM; Das AB; Winterbourn CC; Hampton MB
J Biol Chem; 2020 Jun; 295(23):7839-7848. PubMed ID: 32312750
[TBL] [Abstract][Full Text] [Related]
17. Identification of dihydromyricetin as a natural DNA methylation inhibitor with rejuvenating activity in human skin.
Falckenhayn C; Bienkowska A; Söhle J; Wegner K; Raddatz G; Kristof B; Kuck D; Siegner R; Kaufmann R; Korn J; Baumann S; Lange D; Schepky A; Völzke H; Kaderali L; Winnefeld M; Lyko F; Grönniger E
Front Aging; 2023; 4():1258184. PubMed ID: 38500495
[TBL] [Abstract][Full Text] [Related]
18. SGI-110: DNA Methyltransferase Inhibitor Oncolytic.
Griffiths EA; Choy G; Redkar S; Taverna P; Azab M; Karpf AR
Drugs Future; 2013 Aug; 38(8):535-543. PubMed ID: 26190889
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic priming by hypomethylation enhances the immunogenic potential of tolinapant in T-cell lymphoma.
Ward GA; Zhang Z; Jueliger S; Potapov IS; Davis MP; Boxall AR; Taylor J; Keer H; Biondo A; Lyons JF; Sims M; Smyth T
Cancer Res Commun; 2024 May; ():. PubMed ID: 38727208
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.
Pappalardi MB; Keenan K; Cockerill M; Kellner WA; Stowell A; Sherk C; Wong K; Pathuri S; Briand J; Steidel M; Chapman P; Groy A; Wiseman AK; McHugh CF; Campobasso N; Graves AP; Fairweather E; Werner T; Raoof A; Butlin RJ; Rueda L; Horton JR; Fosbenner DT; Zhang C; Handler JL; Muliaditan M; Mebrahtu M; Jaworski JP; McNulty DE; Burt C; Eberl HC; Taylor AN; Ho T; Merrihew S; Foley SW; Rutkowska A; Li M; Romeril SP; Goldberg K; Zhang X; Kershaw CS; Bantscheff M; Jurewicz AJ; Minthorn E; Grandi P; Patel M; Benowitz AB; Mohammad HP; Gilmartin AG; Prinjha RK; Ogilvie D; Carpenter C; Heerding D; Baylin SB; Jones PA; Cheng X; King BW; Luengo JI; Jordan AM; Waddell I; Kruger RG; McCabe MT
Nat Cancer; 2021 Oct; 2(10):1002-1017. PubMed ID: 34790902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
